EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 275 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Medicare Open Enrollment Starts Tomorrow! October 14, 2021 Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... April 19, 2023 Cancer waiting times: Latest updates and analysis May 11, 2023 Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly... April 20, 2026 Load more HOT NEWS Opinion: ‘We’re making headway, but we can’t be complacent’ Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer Study Adds to Debate about Mammography in Older Women FDA Approves Blood Tests That Can Help Guide Cancer Treatment
